tereotactic radiosurgery (SRS) is a well-established treatment for brain arteriovenous malformations (AVMs) in children. 17 The decision whether to use SRS rather than resection is influenced by a number of factors including clinical presentation, patient age, natural history risk for AVM, location of AVM in eloquent or deep areas, and patient preference. Stereotactic radiosurgery is believed to act by causing a progressive vasculopathy that results in eventual occlusion of vessels within the AVM nidus. This process can take 1-3 years, during which time AVM hemorrhage can occur. In general, the surgical risk should be balanced against the annual risk for hemorrhage after SRS treatment.
less than 18 Gy were used. 26 In that study, the median prescription dose was 18 Gy and the obliteration rate was 35%. Since that time, we have maintained a prospective database of AVM patients and have increased our dose/ volume guidelines for treatment of AVM in children. In the study reported here, we expand our experience with SRS treatment of brain AVMs in children and specifically focus on posttreatment complications and functional outcomes.
Methods

Patients
This study was approved by the Institutional Review Board of the University of California, San Francisco (UCSF) and conducted in compliance with Health Insurance Portability and Accountability Act regulations. The study comprised 2 cohorts of children 18 years of age or younger with brain AVMs treated with SRS. The first cohort consisted of 43 patients who received treatment from 1991 to 1998. Data for these patients were retrospectively collected as part of a prior study 26 and were updated through retrospective review of medical records. Patients who had been excluded from this prior study because of the short duration of their follow-up were included in the present study. The second cohort consisted of 37 children who received treatment from 2000 to 2010 and were identified through the prospective registries of the UCSF Brain Arteriovenous Malformation Study Project and Department of Radiation Oncology. For this study, we retrospectively reviewed these databases, medical records, pre-and post-SRS imaging studies, and clinical follow-up evaluations. Of note, although AVMs in children were treated during the intervening time, data for those patients were not readily available for analysis. Data for both cohorts included presenting symptoms, AVM characteristics (location, volume, Spetzler-Martin grade), and SRS parameters (prescription marginal dose, treated isodose line, number of stages). Modified Pollock radiosurgery-based AVM grading system scores 22 were calculated based on the AVM target volume used for SRS planning. At the time of treatment, all patients were reviewed by a multidisciplinary cerebrovascular team consisting of neurologists, neurosurgeons, interventional neuroradiologists, and radiation oncologists. For patients with larger, less surgically accessible AVMs, SRS is typically recommended instead of microsurgery.
Stereotactic Radiosurgery Technique
For all patients, SRS was performed with a model B, C, 4C, or Leksell Gamma Knife Perfexion (Elekta Instruments). General anesthesia or conscious sedation, based on patient age, was administered by a pediatric anesthesiologist. After administration of local anesthesia, a Leksell head frame was placed. Patients then underwent pre-SRS stereotactic angiography and MRI, including precontrast T1-weighted and Gd-enhanced time-of-flight sequences.
Results of these studies were superimposed to aid in target delineation, which was performed by the attending radiation oncologist and neurosurgeon after the interventional neuroradiologist had outlined the nidus on orthogonal angiograms. The treatment plan was created by a physicist who used GammaPlan treatment planning software (Elekta AB) and approved by the attending radiation oncologist and neurosurgeon. Volume-staged SRS was considered if the treatment volume exceeded 8-10 cm 3 ; for these patients, approximately 8-10 cm 3 was treated per stage at 3-to 6-month intervals. Subsequent registration for staged procedures was accomplished by using anatomical landmarks defined on thin-slice MR images obtained after frame placement. 7 After treatment and recovery from anesthesia, patients were discharged home.
Outcome Measurements
Outcome measures for this study included post-SRS complications (hemorrhage, seizure, headaches, or new neurological deficits) and radiographic outcome (complete vs incomplete obliteration of the AVM) based on 3-year post-SRS follow-up angiography. All post-SRS angiograms were reviewed by a single attending neuroradiologist (S.W.H.) who was blinded as to radiosurgical treatment dose. In addition, for the 2000-2010 cohort, we recorded functional neurological status before and after SRS. Status was based on pediatric, radiation oncology, and neurosurgery clinic notes and was measured by using the modified Rankin Scale (mRS).
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Statistical Analyses
All statistical analyses were performed by using JMP 10.0 software (SAS Institute, Inc.). Univariate analyses were performed on preidentified factors by using the Mann-Whitney U-test for continuous variables (that is, age and prescription dose) and Pearson chi-square tests for categorical variables (that is, Spetzler-Martin grade, patient sex). Multivariate analyses were performed by using a logistic regression model. Survival analysis of time to post-SRS hemorrhage or censorship was also performed, and survival curves were compared with a log-rank test, measuring from the date of the first or only SRS treatment. We considered p values less than 0.05 to be significant.
Results
Patient and AVM Characteristics
We identified 83 children with AVMs treated with SRS at UCSF during the 2 study periods (1991-1998 and 2000-2010) . We excluded from the study 3 patients for whom no follow-up data were available after the date of their SRS treatment. Table 1 lists the baseline characteristics for the remaining 80 patients who constituted our final study cohort, data for each subcohort (1991-1998 and 2000-2010) , and data for a subcohort of 47 patients from either study period for whom 3 or more years of follow-up angiographic data were available. Overall, mean patient age at SRS was 12.7 years; male patients predominated slightly (61%). The most common presenting sign was hemorrhage (56%). The most common AVM location was in the basal ganglia/thalamus (35%), and 64% were in the left hemisphere. No patient had a known family history of hereditary hemorrhagic telangiectasia.
Radiosurgical Treatment
The primary treatment was SRS for 84% of patients. For the remaining patients, prior treatments included subtotal resection and endovascular embolization. In addition, 3 patients had previously undergone SRS at an outside institution and 8 patients had previously undergone treatment with multiple modalities (Table 1) . Table 2 details the SRS parameters for the overall cohort and aforementioned subcohorts. Overall, the median prescription dose was 17.5 Gy (range 12-20 Gy), prescribed to the 50% isodose line for all but 9 patients. Radiosurgery was staged for 25% of patients (2 stages for 16%, 3 stages for 9%). For patients who underwent staged SRS, the median time between the first and final stage was 7 months. (14) 12 (32) 18 (23) 9 (19) V 3 (7) 4 (11) 7 (9) 2 (4) * Comparison of 1991-1998 and 2000-2010 cohorts. Boldface indicates statistical significance. † Other presentations included increasing head circumference (n = 1), diplopia (n = 1), and incidental finding during workup for multiple congenital abnormalities (n = 2) and a posterior fossa tumor (n = 1). ‡ Eight patients underwent prior treatments with multiple modalities. § AVM volume data were not available for 4 patients in the 1991-1998 cohort; these patients were not part of the 3-year angiographic cohort.
Differences Between Cohorts
Several significant differences were detected between the 2 cohorts (Tables 1 and 2 ), reflecting changes in practice patterns at UCSF. Differences in mean patient age (11.8 vs 13.9 years, p = 0.009), modified Pollock score (1.1 vs 1.5, p = 0.015), and Spetzler-Martin grades (21% vs 43% Grade IV or V, p = 0.03) indicated increased complexity of the AVMs being treated with SRS in the more recent cohort. Although the overall proportion of patients who had undergone prior treatments did not differ, prior subtotal resection had been performed for 22% of patients in the 2000-2010 cohort and no patients in the 1991-1998 cohort (p = 0013). In addition, SRS was staged for more patients in the 2000-2010 cohort than in the earlier cohort (38% vs 12%, respectively, p = 0.006). Notably, the unbalanced mean prescription marginal doses did not significantly differ between the 1991-1998 and 2000-2010 cohorts (p = 0.19). However, when AVM volume was controlled for, least-squares analysis showed that the mean prescription dose increased from 16.5 Gy for the 1991-1998 cohort to 17.7 Gy for the 2000-2010 cohort (p = 0.0019; Fig. 1 ).
Angiographic Outcomes
Angiographic evaluation was performed 3 years after SRS treatment for 47 patients (59%). A complete response was seen for 16 patients (34%), and an incomplete response was seen for the remaining 31 (66%). Univariate logistic regression identified higher prescription dose (p = 0.006; Fig. 2 ) and target volume (p = 0.038) as being significantly associated with complete obliteration. When tested as a dichotomous variable, higher prescription dose was also significantly associated with angiographic obliteration (≥ 18 vs < 18 Gy, p = 0.015, Fisher exact test). Factors not associated with angiographic response included patient age (p = 0.56), hemorrhage at presentation (p = 0.07), Pollock score (p = 0.067), and Spetzler-Martin score (p = 0.77). Because our target volume is used to guide prescription dose, 26 we analyzed the association between these 2 variables and found a weak but significant association between prescription dose and the log of the target volume (R 2 = 0.16, p = 0.005, 1-way ANOVA). A logistic regression model incorporating prescription dose and log(target volume) showed a significant association between these 2 variables and angiographic outcome (overall model p = 0.02, prescription dose p = 0.03, log[target volume] p = 0.75).
Complications Associated With Treatment
Overall, a post-SRS complication was recorded for 38 patients (48%), among whom multiple complications were recorded for 13 (16%). Posttreatment hemorrhage occurred in 16 patients (20%), 1 of whom died. The cumulative incidence of hemorrhage 5 years after SRS was 25% (95% CI 16%-37%) (Fig. 3) . The median time to hemorrhage was 15 months (range 4-136 months). For 11 patients (69%) who experienced posttreatment hemorrhage, the hemorrhage occurred during the radiosurgical latency period (defined as within 3 years after the first stage of treatment). Of these patients, 10 underwent * Of the total group, 71 patients (89%) received treatment to the 50% isodose line; for the remaining 9 patients, the isodose line varied from 40% to 90%. † For patients who underwent staged SRS.
3-year follow-up angiography; all angiograms revealed a residual AVM nidus. Of note, 7 patients who experienced post-SRS hemorrhages had undergone staged SRS, but for only 2 did hemorrhage occur before completion of the final stage of SRS. Hemorrhage was more likely among patients who received a dose of less than 18 Gy than among those who received 18-20 Gy ( Fig. 3 ; Table 3 ). Table 3 details the proportion of patients for whom SRS-related complications during follow-up were documented (mean 50 months, median 46 months, range 2-187 months). No patient experienced hemorrhage after angiographically documented AVM obliteration.
Additional Treatments
A total of 25 patients (31%) underwent subsequent treatment for residual AVM. Of these, 18 patients underwent salvage SRS, 6 resection, 2 endovascular embolization alone, and 1 salvage SRS followed by resection. Follow-up images were available for 12 of these patients. Of the patients who underwent salvage SRS, complete obliteration was seen on long-term images for 3 patients; on MR images taken 1 at year after salvage SRS, reduced AVM shunting was seen for 1 patient and no change was seen for 1 patient. Of the 6 patients who ultimately underwent surgery, complete resection was achieved for 4 and partial resection for 2. One patient with a giant hemispheric AVM underwent palliative embolization for severe headaches, which improved modestly after this treatment.
Functional Outcome
For 32 of the 37 patients in the 2000-2010 cohort, functional status was measured before SRS and at the time of the last follow-up visit (Fig. 4) . Mean time to followup mRS measurement was 2.9 years (median 2.4 years, range 2.5 months to 7.9 years). Good outcomes (mRS Score 0-2) were seen for 25 patients (78%); of these, improvement or no change from pre-SRS functional baseline was noted for 21 patients (66%) and worsening was noted for 11 patients. Of the 11 patients with worsened functional status, 5 experienced hemorrhages during the follow-up time and the remaining 6, although worsened, still had mRS scores of 1 or 2. One patient in this series died of posttreatment hemorrhage.
Discussion
The reported efficacy of SRS for the treatment of brain AVMs in children varies widely (Table 4) . Definitive conclusions from studies to date are difficult to reach because of variations in duration of follow-up, patient selection criteria, and SRS parameters used to treat pediatric AVMs. In the present study, we report a series of children with AVM treated with a relatively low prescription marginal dose and describe angiographic outcomes, rates of posttreatment hemorrhage, other treatment-related ad- verse events, and functional outcomes. Several differences exist between our population and previously reported populations. For our study population, we favored a lower prescription marginal dose (median 17.5 Gy) and tended to treat larger, more complex AVMs with SRS and smaller and less complex AVMs with resection. When compared with other studies that reported median target volumes, in our study, median target volumes did not differ substantially, but the proportion of patients with Spetzler-Martin Grades IV or V was higher (Table 4) . Our practice has changed with time, as can be seen in the differences between the 1990-1998 and 2000-2010 cohorts. Our practice is to follow a dose-volume toxicity curve 26 and to use lower doses for larger volumes. From our initial experience using SRS to treat AVMs in children, we found that a prescription dose of 18 Gy or more was associated with an improved rate of obliteration. 26 On the basis of this finding, we slightly increased our marginal doses for a given AVM volume (Fig. 1) . In addition, we have taken a more aggressive stance with microsurgical management of small and low-grade AVMs. SRS is therefore now used for larger AVMs and more often used for patients who have undergone prior attempts at resection.
In this study, we found that prescription dose is a critical factor associated with both obliteration and posttreatment hemorrhage; our lower prescription doses therefore probably explain our lower rates of obliteration (34% at 3 years). The overall prescription marginal doses used ranged from 12 to 20 Gy. Several studies have advocated for higher doses of at least 20 Gy. Most recently, Dinca et al. reported a large series of children with AVM treated with Gamma Knife radiosurgery. 5 Nearly all of those patients received prescription marginal doses of 20-25 Gy. At those high prescription doses, Dinca et al. found no differences in angiographic outcomes; obliteration rate for patients undergoing SRS for the first time was 71%, and the rate of posttreatment hemorrhage was only 2.2%. Because only 4 patients received less than 20 Gy, these authors could not comment on the efficacy of lower prescription doses. In our series, however, our highest doses (18) (19) (20) still only resulted in a 3-year angiographic obliteration rate of 52%. Of note, the rate of hemorrhage for this higher dose group was only 3%, comparable to that reported by Dinca et al. Although AVM obliteration is clearly protective against posttreatment hemorrhage, 20 these data suggest that SRS of at least 18 Gy might pro- (11) 13 (16) vide protection from posttreatment hemorrhage even if only a partial response is obtained. Given our low rate of obliteration among patients who received less than 18 Gy (35%), however, lower doses do not seem to offer similar protection.
With regard to other post-SRS complications, we included not only neurological deficits but also symptoms of brain edema (headache, nausea/vomiting) and new or worsening seizures (Table 3) . We identified no permanent neurological deficits that were not associated with posttreatment hemorrhage and found only 1 patient in whom temporary posttreatment neurological deficits developed. The most common posttreatment complications not associated with hemorrhage were headaches and seizures, experienced by 21% and 20% of patients, respectively. For 5 patients, posttreatment headaches were managed with decadron, which was also used (in addition to increasing antiepileptic medications) in 1 patient after worsening of seizures. Overall, our prescription dose effectively minimized posttreatment neurological deficits related directly to SRS. However, this benefit was negated by lower rates of obliteration and higher rates of posttreatment hemorrhage.
Few studies of SRS for AVMs in children have reported changes in functional status based on mRS scores, a well-established measure of neurological function. 6 A given patient's functional outcome after SRS for an AVM is dependent on that patient's pretreatment functional status, any adverse events that occur after treatment (either directly treatment-related or otherwise), and that patient's ability to recover from any insults at the time of presentation and/or posttreatment adverse events. Thus, mRS scores provide a general sense of the entire treatment and recovery process. This measure also distinguishes between patients with no symptoms or functional disabilities (mRS Score 0) and those with mild symptoms that do not impair function (mRS Score 1). More than half of the patients in our series with "worsened" functional status at last follow-up visit actually had what would be considered a "good" mRS score (1 or 2). Subtle changes in symptoms can result from overt motor or sensory deficits as well as other potential SRS-associated adverse effects, such as seizures, headache, nausea/vomiting, or cognitive deficits. Although 5 of the 11 patients in this series with worsened functional status experienced posttreatment hemorrhages, the remainder experienced headaches, seizures, or both, and all had mRS scores of 1 or 2 at the time of last follow-up visit. Of course, even more subtle neurological symptoms, such as cognitive deficits, are often difficult to detect without detailed neuropsychological examination. Yeon et al. 30 specifically evaluated patients' school performance and determined that performance declined after treatment for 44% of AVM patients who underwent SRS. Such findings emphasize the need for neuropsychological evaluations in future studies of SRS in the pediatric population.
Conclusions
SRS is a useful tool in the management of brain AVMs in children, but the safety profile and necessary SRS parameters still require elucidation. In this study, a low marginal dose minimized overt neurological deficits directly associated with SRS but also resulted in lower rates of obliteration and higher rates of posttreatment hemorrhage. On the basis of this experience, we recommend marginal doses of at least 18 Gy to improve obliteration rates and reduce the risk for posttreatment hemorrhage. Comparison of our results with those of prior studies that used higher prescription doses (≥ 20 Gy), however, suggests that even better angiographic results and reasonable complication rates can be obtained when higher doses are used. In addition, aggressive follow-up and consideration of salvage SRS should be implemented for these patients. With multiple treatment options for brain AVMs in children, an understanding of the risks and benefits of SRS is critical for optimizing patient outcomes. For further clarification of the potential risks of SRS, prospective studies incorporating detailed neurological and cognitive assessments are needed.
